エピジェネティクス市場：製品別（キット、試薬、酵素、機器）、用途別（腫瘍、非腫瘍）、エンドユーザー別（学術・研究機関、製薬・バイオテクノロジー企業、研究受託機関）。世界の機会分析および産業予測、2020-2030年

Epigenetics Market By Product (Kits, Reagents, Enzymes, Instruments), By Application (Oncology, Non Oncology), By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2020-2030

世界のエピジェネティクス市場は、2020年には10億1810万ドルで、2021年から2030年にかけてCAGR14.8%を記録し、2030年には40億5686万ドルに達すると予測されています。エピジェネティクスとは、遺伝学の一分野で... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年5月31日	US$5,769 シングルユーザーライセンスライセンス・価格情報・注文方法はこちら	286	英語

サマリー

世界のエピジェネティクス市場は、2020年には10億1810万ドルで、2021年から2030年にかけてCAGR14.8%を記録し、2030年には40億5686万ドルに達すると予測されています。
エピジェネティクスとは、遺伝学の一分野であり、遺伝子のオン・オフや、遺伝子型の変化に影響されずに遺伝子を読み取る細胞能力に影響を与える、外部または生態的側面によって引き起こされる細胞および生理学的形質の変化を研究するものである。エピジェネティクスとは、ゲノム配列の変化に加え、生物の表現型が変化することを意味し、DNAやRNAの配列は変化しません。エピジェネティックな変化は、環境刺激に対してダイナミックに変化するため、発生に不可欠である。しかし、これらの変化は安定的で、世代を超えて受け継がれる可能性があります。ほとんどの生物の生物学と遺伝子発現はエピジェネティクスに影響されており、発生遺伝学と分子生物学において最も重要な分野の一つとなっている。メチル化、アセチル化、リン酸化、ユビキチン化、サモル化などが、発見されているエピジェネティクス機構の一部である。
エピジェネティクス市場は、がんの発生率の増加や、心血管疾患、代謝性疾患、感染症、炎症性疾患などの慢性疾患への応用の急増により、予測期間中に大きく成長することが期待されています。研究開発活動の増加、研究開発への投資の急増、がん以外の疾患へのエピジェネティック・アプリケーションの成長、学術・製薬・バイオテクノロジー企業間の提携の増加が市場の成長を大きく後押ししています。しかし、装置のコストが高く、訓練を受けた専門家の不足が市場の成長を阻害しています。
さらに、新興市場の未開発の潜在能力は、市場参加者に有利な機会を提供します。さらに、病気の発症や進行の基礎となるエピジェネティクスプロセスの応用の増加は、患者を評価するための革新的な早期診断および予後バイオマーカーの創出や精密医療におけるその活用にとって、近年重要であることが証明されています。
エピジェネティクス市場は、製品、アプリケーション、エンドユーザー、地域によって区分されます。製品別では、酵素、キット、機器、試薬に分類されます。酵素は、DNAリガーゼ、DNAポリメラーゼ、その他のDNA修飾酵素、アセチラーゼ、メチルトランスフェラーゼ、その他のタンパク質修飾酵素、逆転写酵素、RNAリガーゼ、その他のRNA修飾酵素に分類されます。キット分野は、さらにChIPシーケンスキット、バイサルファイト変換キット、全ゲノム増幅キット、5-hmC & 5-mC解析キット、RNAシーケンスキットなどに細分化されています。機器セグメントは、さらに質量分析計、次世代シーケンサー、qPCR、ソニケーター、その他に分類されます。試薬セグメントはさらに、抗体、バッファー、ヒストン、磁気ビーズ、プライマー、その他に分類されます。
アプリケーション別では、がん領域と非がん領域に分類されます。オンコロジー分野はさらに、固形腫瘍と液状腫瘍に細分化されます。非オンコロジー分野には、代謝性疾患、感染症、炎症性疾患、心血管疾患、およびその他のアプリケーションが含まれます。エンドユーザー別では、学術・政府研究機関、製薬・バイオテクノロジー企業、開発業務受託機関（CRO）に分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。
本レポートで紹介する主要企業は、Abcam Plc.、Active Motif, Inc.、Agilent Technologies, Inc.、Hologic Inc. (Diagenode), Illumina Inc.、Merck KGaA (Merck Millipore), PerkinElmer, Inc, QIAGEN N.V., Thermo Fisher Scientific Inc.と Zymo Researchです。

ページTOPに戻る

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: EPIGENETICS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Kits
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Reagents
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Enzymes
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Instruments
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: EPIGENETICS MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oncology
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Non Oncology
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: EPIGENETICS MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Academic and Research Institutes
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Pharmaceutical and Biotechnology Companies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Contract Research Organizations
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: EPIGENETICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Product
7.2.3 North America Market size and forecast, by Application
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Product
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Product
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Product
7.2.5.3.2 Market size and forecast, by Application
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Product
7.3.3 Europe Market size and forecast, by Application
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Product
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Product
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Product
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Product
7.3.5.4.2 Market size and forecast, by Application
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Product
7.3.5.5.2 Market size and forecast, by Application
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Product
7.3.5.6.2 Market size and forecast, by Application
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Product
7.4.3 Asia-Pacific Market size and forecast, by Application
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Product
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Product
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Product
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Product
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Product
7.4.5.5.2 Market size and forecast, by Application
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Product
7.4.5.6.2 Market size and forecast, by Application
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Product
7.5.3 LAMEA Market size and forecast, by Application
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Middle East And Africa
7.5.5.1.1 Market size and forecast, by Product
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Latin America
7.5.5.2.1 Market size and forecast, by Product
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Abcam Plc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Active Motif, Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Agilent Technologies, Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Hologic Inc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Illumina Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck Millipore
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 PerkinElmer, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 QIAGEN N.V.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Thermo Fisher Scientific Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Zymo Research
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. EPIGENETICS MARKET REVENUE, FOR KITS, BY REGION , 2020-2030,($MILLION)
TABLE 3. EPIGENETICS MARKET KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. EPIGENETICS MARKET REVENUE, FOR REAGENTS, BY REGION , 2020-2030,($MILLION)
TABLE 5. EPIGENETICS MARKET REAGENTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. EPIGENETICS MARKET REVENUE, FOR ENZYMES, BY REGION , 2020-2030,($MILLION)
TABLE 7. EPIGENETICS MARKET ENZYMES BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. EPIGENETICS MARKET REVENUE, FOR INSTRUMENTS, BY REGION , 2020-2030,($MILLION)
TABLE 9. EPIGENETICS MARKET INSTRUMENTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 10. GLOBAL EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 11. EPIGENETICS MARKET REVENUE, FOR ONCOLOGY, BY REGION , 2020-2030,($MILLION)
TABLE 12. EPIGENETICS MARKET ONCOLOGY BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. EPIGENETICS MARKET REVENUE, FOR NON ONCOLOGY, BY REGION , 2020-2030,($MILLION)
TABLE 14. EPIGENETICS MARKET NON ONCOLOGY BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. GLOBAL EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 16. EPIGENETICS MARKET REVENUE, FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION , 2020-2030,($MILLION)
TABLE 17. EPIGENETICS MARKET ACADEMIC AND RESEARCH INSTITUTES BY COUNTRY, 2020-2030,($MILLION)
TABLE 18. EPIGENETICS MARKET REVENUE, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION , 2020-2030,($MILLION)
TABLE 19. EPIGENETICS MARKET PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY COUNTRY, 2020-2030,($MILLION)
TABLE 20. EPIGENETICS MARKET REVENUE, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION , 2020-2030,($MILLION)
TABLE 21. EPIGENETICS MARKET CONTRACT RESEARCH ORGANIZATIONS BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. EPIGENETICS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 23. NORTH AMERICA EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 24. NORTH AMERICA EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 25. NORTH AMERICA EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 26. NORTH AMERICA EPIGENETICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 27. U.S. EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 28. U.S. EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 29. U.S. EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 30. CANADA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 31. CANADA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 32. CANADA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 33. MEXICO EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 34. MEXICO EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 35. MEXICO EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 36. EUROPE EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 37. EUROPE EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 38. EUROPE EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 39. EUROPE EPIGENETICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 40. GERMANY EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 41. GERMANY EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 42. GERMANY EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 43. FRANCE EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 44. FRANCE EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 45. FRANCE EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 46. U.K. EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 47. U.K. EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 48. U.K. EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 49. ITALY EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 50. ITALY EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 51. ITALY EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 52. SPAIN EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 53. SPAIN EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 54. SPAIN EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 55. REST OF EUROPE EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 56. REST OF EUROPE EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 57. REST OF EUROPE EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 58. ASIA-PACIFIC EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 59. ASIA-PACIFIC EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 60. ASIA-PACIFIC EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 61. ASIA-PACIFIC EPIGENETICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 62. JAPAN EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 63. JAPAN EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 64. JAPAN EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 65. CHINA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 66. CHINA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 67. CHINA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 68. AUSTRALIA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 69. AUSTRALIA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 70. AUSTRALIA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 71. INDIA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 72. INDIA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 73. INDIA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 74. SOUTH KOREA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 75. SOUTH KOREA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 76. SOUTH KOREA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 77. REST OF ASIA-PACIFIC EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 78. REST OF ASIA-PACIFIC EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 79. REST OF ASIA-PACIFIC EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 80. LAMEA EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 81. LAMEA EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 82. LAMEA EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 83. LAMEA EPIGENETICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 84. MIDDLE EAST AND AFRICA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 85. MIDDLE EAST AND AFRICA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 86. MIDDLE EAST AND AFRICA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 87. LATIN AMERICA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 88. LATIN AMERICA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 89. LATIN AMERICA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 90.ABCAM PLC.: COMPANY SNAPSHOT
TABLE 91.ABCAM PLC.: OPERATING SEGMENTS
TABLE 92.ABCAM PLC.: PRODUCT PORTFOLIO
TABLE 93.ABCAM PLC.: NET SALES,
TABLE 94.ABCAM PLC.: KEY STRATERGIES
TABLE 95.ACTIVE MOTIF, INC.: COMPANY SNAPSHOT
TABLE 96.ACTIVE MOTIF, INC.: OPERATING SEGMENTS
TABLE 97.ACTIVE MOTIF, INC.: PRODUCT PORTFOLIO
TABLE 98.ACTIVE MOTIF, INC.: NET SALES,
TABLE 99.ACTIVE MOTIF, INC.: KEY STRATERGIES
TABLE 100.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 101.AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
TABLE 102.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 103.AGILENT TECHNOLOGIES, INC.: NET SALES,
TABLE 104.AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 105.HOLOGIC INC.: COMPANY SNAPSHOT
TABLE 106.HOLOGIC INC.: OPERATING SEGMENTS
TABLE 107.HOLOGIC INC.: PRODUCT PORTFOLIO
TABLE 108.HOLOGIC INC.: NET SALES,
TABLE 109.HOLOGIC INC.: KEY STRATERGIES
TABLE 110.ILLUMINA INC.: COMPANY SNAPSHOT
TABLE 111.ILLUMINA INC.: OPERATING SEGMENTS
TABLE 112.ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 113.ILLUMINA INC.: NET SALES,
TABLE 114.ILLUMINA INC.: KEY STRATERGIES
TABLE 115.MERCK MILLIPORE: COMPANY SNAPSHOT
TABLE 116.MERCK MILLIPORE: OPERATING SEGMENTS
TABLE 117.MERCK MILLIPORE: PRODUCT PORTFOLIO
TABLE 118.MERCK MILLIPORE: NET SALES,
TABLE 119.MERCK MILLIPORE: KEY STRATERGIES
TABLE 120.PERKINELMER, INC.: COMPANY SNAPSHOT
TABLE 121.PERKINELMER, INC.: OPERATING SEGMENTS
TABLE 122.PERKINELMER, INC.: PRODUCT PORTFOLIO
TABLE 123.PERKINELMER, INC.: NET SALES,
TABLE 124.PERKINELMER, INC.: KEY STRATERGIES
TABLE 125.QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 126.QIAGEN N.V.: OPERATING SEGMENTS
TABLE 127.QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 128.QIAGEN N.V.: NET SALES,
TABLE 129.QIAGEN N.V.: KEY STRATERGIES
TABLE 130.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 131.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
TABLE 132.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 133.THERMO FISHER SCIENTIFIC INC.: NET SALES,
TABLE 134.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
TABLE 135.ZYMO RESEARCH: COMPANY SNAPSHOT
TABLE 136.ZYMO RESEARCH: OPERATING SEGMENTS
TABLE 137.ZYMO RESEARCH: PRODUCT PORTFOLIO
TABLE 138.ZYMO RESEARCH: NET SALES,
TABLE 139.ZYMO RESEARCH: KEY STRATERGIES

LIST OF FIGURES
FIGURE 1.EPIGENETICS MARKET SEGMENTATION
FIGURE 2.EPIGENETICS MARKET,2020-2030
FIGURE 3.EPIGENETICS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.EPIGENETICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.EPIGENETICS MARKET,BY PRODUCT,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF KITS EPIGENETICS MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF REAGENTS EPIGENETICS MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ENZYMES EPIGENETICS MARKET,2020-2030(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INSTRUMENTS EPIGENETICS MARKET,2020-2030(%)
FIGURE 16.EPIGENETICS MARKET,BY APPLICATION,2020(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY EPIGENETICS MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF NON ONCOLOGY EPIGENETICS MARKET,2020-2030(%)
FIGURE 19.EPIGENETICS MARKET,BY END USER,2020(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ACADEMIC AND RESEARCH INSTITUTES EPIGENETICS MARKET,2020-2030(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES EPIGENETICS MARKET,2020-2030(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS EPIGENETICS MARKET,2020-2030(%)
FIGURE 23.EPIGENETICS MARKET BY REGION,2020
FIGURE 24.U.S. EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 25.CANADA EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 26.MEXICO EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 27.GERMANY EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 28.FRANCE EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 29.U.K. EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 30.ITALY EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 31.SPAIN EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 32.REST OF EUROPE EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 33.JAPAN EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 34.CHINA EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 35.AUSTRALIA EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 36.INDIA EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 37.SOUTH KOREA EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 38.REST OF ASIA-PACIFIC EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 39.MIDDLE EAST AND AFRICA EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 40.LATIN AMERICA EPIGENETICS MARKET,2020-2030($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45.COMPETITIVE DASHBOARD
FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 47.ABCAM PLC..: NET SALES ,($MILLION)
FIGURE 48.ACTIVE MOTIF, INC..: NET SALES ,($MILLION)
FIGURE 49.AGILENT TECHNOLOGIES, INC..: NET SALES ,($MILLION)
FIGURE 50.HOLOGIC INC..: NET SALES ,($MILLION)
FIGURE 51.ILLUMINA INC..: NET SALES ,($MILLION)
FIGURE 52.MERCK MILLIPORE.: NET SALES ,($MILLION)
FIGURE 53.PERKINELMER, INC..: NET SALES ,($MILLION)
FIGURE 54.QIAGEN N.V..: NET SALES ,($MILLION)
FIGURE 55.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
FIGURE 56.ZYMO RESEARCH.: NET SALES ,($MILLION)

ページTOPに戻る

Table of Contents

Summary

The global epigenetics market was valued at $1,018.1 million in 2020, and is projected to reach $4,056.86 million by 2030, registering a CAGR of 14.8% from 2021 to 2030.
Epigenetics is a stream of genetics that involves study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect cellular ability to read genes without being affected by changes in genotype. Epigenetics itself means in addition to alterations in genomic sequence, which means it results into changes in an organism’s phenotype rather than genotype, wherein the underlying DNA or RNA sequence remains unchanged. Epigenetic alterations are essential for development as they are dynamic and change with respect to environmental stimuli. However, these changes can be stable and could be passed from one generation to another. Biology and genetic expressions of most organisms are affected by epigenetics, which makes it one of the most crucial fields of developmental genetics and molecular biology. Methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation are some of the epigenetic mechanisms that have been discovered.
The epigenetics market is expected to grow significantly during the forecast period, owing to rise in incidences of cancer and surge in its application in other chronic diseases such as cardiovascular disorders, metabolic diseases, infectious diseases, and inflammatory diseases. Increase in R&D activities, surge in investments in R&D, growth in epigenetic applications for non-oncology diseases, and increase in partnership between academic, pharmaceutical, and biotechnology companies significantly drive the market growth. However, high cost of instruments and lack of trained professionals impede the market growth.
Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players. Moreover, rise in application of epigenetics processes underlying illness onset and progression has proven critical in recent years for creation of innovative early diagnostic and prognosis biomarkers for assessing patients and its utilization in precision medicine.
The epigenetics market is segmented on the basis of product, application, end user, and region. By product, it is divided into enzymes, kits, instruments, and reagents. The enzymes segment is further divided into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. The kits segment is further subdivided into ChIP sequencing kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC & 5-mC analysis kits, and RNA sequencing kits, and others. The instrument segment is further categorized into mass spectrometers, next-generation sequencers, qPCRs, sonicators, and others. The reagents segment is further divided into antibodies, buffers, histones, magnetic beads, primers, and others.
On the basis of application, the market is segmented into oncology and non-oncology. The oncology segment is further sub segmented into solid tumors and liquid tumors. Non-oncology applications include metabolic diseases, infectious diseases, inflammatory diseases, cardiovascular diseases, and other applications. By end user, it is segmented into academic & government research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs). By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players profiled in the report are Abcam Plc., Active Motif, Inc., Agilent Technologies, Inc., Hologic Inc. (Diagenode), Illumina Inc., Merck KGaA (Merck Millipore), PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Zymo Research.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（oncology）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（oncology）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?